Navigation Links
NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing
Date:12/8/2010

e Company's ability to refinance or repay loans received; the Company's uncertain business condition; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Contact:China Shenghuo Pharmaceutical Holdings, Inc.Ms. Shujuan WangSecretary of the Board of DirectorsEmail: wangshujuan@chinashenghuo.netTel: +86-871-728-2698
'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
8. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
9. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
10. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
11. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:5/4/2015)... NC (PRWEB) May 04, 2015 ... provider created a stir and showed the healthcare ... a major healthcare procedure, the downside of balance ... of a healthcare provider billing a patient for ... chooses to reimburse and what the provider chooses ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Hinds, Eric Gladen’s documentary Trace Amounts, and Allison Folmar, ... annual autism conference held internationally. , On Sunday, May ... Is recovery from autism possible?" Are you interested in ... You’re In There: winning our war against autism ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Women’s ... their Facebook page. , Their Facebook page ... many services the Practice has, it’s multiple locations, Providers ... Women’s Excellence has a very strong social media presence, ... and You Tube. , Women’s Excellence is the ...
Breaking Medicine News(10 mins):Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
... , WASHINGTON, July 22 The ... Tobacco-Free Kids: , , The U.S. ... so-called electronic cigarettes by seeking to block importation of these products ... potential health risks of these products. The FDA announced today ...
... , PORTLAND, Ore., July 22 For ... originally created and produced videos developed for myRegence.com , a health ... The 30th Annual Telly Awards are widely considered to be ... from more than 14,000 entries worldwide. , , ...
... , , OWINGS MILLS, Md., July 22 ... MED ), our Directors, Employees and Associates are delighted that ... been nominated by President Obama, and confirmed by the U.S. Senate, as ... , Gen. McCarthy has served his country in ...
... SAN DIEGO, July 22 Orexigen Therapeutics, Inc. (Nasdaq: ... market and other conditions, 9,000,000 shares of its common stock in ... to grant to the underwriter a 30-day option to purchase up ... if any. All of the shares are being offered by Orexigen. ...
... , , MENLO PARK, Calif., July ... results for the second quarter ended July 3, 2009. , ... revenues increased 11% to $60,862,000, as compared to $54,956,000 in the second ... as compared to $50,801,000 in the second quarter of 2008. Net ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 2Health News:FDA Acts to Protect Public Health from Electronic Cigarettes 3Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 2Health News:Medifast Independent Director Lt. Gen. Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 3Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Exponent Reports Second Quarter 2009 Results 2Health News:Exponent Reports Second Quarter 2009 Results 3Health News:Exponent Reports Second Quarter 2009 Results 4Health News:Exponent Reports Second Quarter 2009 Results 5Health News:Exponent Reports Second Quarter 2009 Results 6Health News:Exponent Reports Second Quarter 2009 Results 7Health News:Exponent Reports Second Quarter 2009 Results 8Health News:Exponent Reports Second Quarter 2009 Results 9
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
Medicine Products: